CXCL10 and neoplasm: Although Pemetrexed and cisplatin (PEM/CDDP) chemotherapy combined with ICIs did not have the synergic effect in patients with metastatic NSCLC, the combination regimen with MEK inhibitors (MEKi) blocking autophagy could trigger the CXCL10 secretion and CD8+ T cell recruitment to enhance the tumor-killing effect (146).